Literature DB >> 8719743

Deficiency of merosin (laminin M or alpha 2) in congenital muscular dystrophy associated with cerebral white matter alterations.

M Vainzof1, S K Marie, U C Reed, J S Schwartzman, R C Pavanello, M R Passos-Bueno, M Zatz.   

Abstract

Recently, a deficiency of merosin has been reported in patients with classical congenital muscular dystrophy (CMD), while other patients, with indistinguishable clinico-pathological features, do not present this deficiency, suggesting genetic heterogeneity. The purpose of the present investigation was to assess merosin distribution and quantity in 21 clinically well characterized Brazilian CMD patients, in order to: a) estimate the proportion of merosin-deficient cases in this group of patients; b) characterize phenotypically merosin-negative, as compared to merosin-positive patients. Merosin deficiency was found in 11 patients and all the seven who had been submitted to neuroimaging studies showed evidence of periventricular dysmyelination. A normal pattern of 43 DAG was found in all patients, which suggest that this protein is not preferentially involved in a third form of merosin-positive CMD. Results from the present study are further suggestive, but do not prove, that the association of merosin deficiency with white matter alterations represents a genetic entity with common clinical, laboratory and neuroimaging findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719743     DOI: 10.1055/s-2007-979777

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  5 in total

1.  Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23.

Authors:  D N Messina; M C Speer; M A Pericak-Vance; E M McNally
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

2.  PCR based mutation screening of the laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for founder effects in congenital muscular dystrophy.

Authors:  P Guicheney; N Vignier; X Zhang; Y He; C Cruaud; V Frey; A Helbling-Leclerc; P Richard; B Estournet; L Merlini; H Topaloglu; M Mora; J P Harpey; C A Haenggeli; A Barois; B Hainque; K Schwartz; F M Tomé; M Fardeau; K Tryggvason
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

Review 3.  The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.

Authors:  K J Jones; G Morgan; H Johnston; V Tobias; R A Ouvrier; I Wilkinson; K N North
Journal:  J Med Genet       Date:  2001-10       Impact factor: 6.318

Review 4.  Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases.

Authors:  Toshihiro Masaki; Kiichiro Matsumura
Journal:  J Biomed Biotechnol       Date:  2010-06-15

Review 5.  Consensus statement on standard of care for congenital muscular dystrophies.

Authors:  Ching H Wang; Carsten G Bonnemann; Anne Rutkowski; Thomas Sejersen; Jonathan Bellini; Vanessa Battista; Julaine M Florence; Ulrike Schara; Pamela M Schuler; Karim Wahbi; Annie Aloysius; Robert O Bash; Christophe Béroud; Enrico Bertini; Kate Bushby; Ronald D Cohn; Anne M Connolly; Nicolas Deconinck; Isabelle Desguerre; Michelle Eagle; Brigitte Estournet-Mathiaud; Ana Ferreiro; Albert Fujak; Nathalie Goemans; Susan T Iannaccone; Patricia Jouinot; Marion Main; Paola Melacini; Wolfgang Mueller-Felber; Francesco Muntoni; Leslie L Nelson; Jes Rahbek; Susana Quijano-Roy; Caroline Sewry; Kari Storhaug; Anita Simonds; Brian Tseng; Jiri Vajsar; Andrea Vianello; Reinhard Zeller
Journal:  J Child Neurol       Date:  2010-11-15       Impact factor: 1.987

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.